Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01182441|
Recruitment Status : Unknown
Verified March 2013 by Boston Scientific Corporation.
Recruitment status was: Active, not recruiting
First Posted : August 16, 2010
Last Update Posted : January 27, 2015
This is a prospective, randomized, multicenter study to provide additional information on the safety and efficacy of the WATCHMAN LAA Closure Technology.
The PREVAIL study was amended to initiate a prospective, non-randomized continued access study titled "Continued Access to PREVAIL (CAP2)" to collect additional information on the safety and efficacy of the WATCHMAN LAA closure technology. The study is estimated to enroll an initial cohort of 300 subjects with a maximum of 1500 subjects, at 60 investigational sites in the U.S.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Stroke||Device: WATCHMAN Device Drug: Warfarin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||475 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||January 2013|
|Estimated Study Completion Date :||August 2017|
Subjects assigned to receive the WATCHMAN device.
Device: WATCHMAN Device
WATCHMAN Left Atrial Appendage Closure Technology
Active Comparator: Warfarin
Subjects assigned to warfarin therapy.
Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
Other Name: Coumadin
- Primary Endpoints [ Time Frame: 18 month rates ]7-Day procedure rate of death, ischemic stroke, systemic embolism and complications requiring major cardiovascular or endovascular intervention; Comparison of the composite of stroke, systemic embolism and cardiovascular/unexplained death; Comparison of ischemic stroke and systemic embolism occurring greater than 7 days post randomization.
- Predefined Additional Analyses [ Time Frame: 18 month rates and acute procedure rates ]Device and procedure related events; Mortality; New versus experienced operators; Sensitivity analyses for post procedure population, per protocol #1 population and per protocol #2 population
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01182441
Show 41 Study Locations
|Principal Investigator:||David R. Holmes, M.D.||Mayo Clinic|
|Principal Investigator:||Vivek Y. Reddy, M.D.||Icahn School of Medicine at Mount Sinai|